Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms
about
Understanding natural herpes simplex virus immunity to inform next-generation vaccine designDistinct APC subtypes drive spatially segregated CD4+ and CD8+ T-cell effector activity during skin infection with HSV-1Protective Role of Fas-FasL Signaling in Lethal Infection with Herpes Simplex Virus Type 2 in MiceA caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goatsDiversity in CD8(+) T cell function and epitope breadth among persons with genital herpes.Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection.Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virusIn vivo requirement for Atg5 in antigen presentation by dendritic cells.Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection.Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-γ response.Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functionsRole of Fas/FasL in regulation of inflammation in vaginal tissue during HSV-2 infection.Innate and adaptive immune responses to herpes simplex virusEarly resolution of herpes simplex virus type 2 infection of the murine genital tract involves stimulation of genital parenchymal cells by gamma interferonMice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1The Role of Plasmacytoid Dendritic Cells in Innate and Adaptive Immune Responses against Alpha Herpes Virus InfectionsThe combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South AfricaIncreased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders.Therapeutic Use of Soluble Fas Ligand Ameliorates Acute and Recurrent Herpetic Stromal Keratitis in MiceImpaired Fas-Fas Ligand Interactions Result in Greater Recurrent Herpetic Stromal Keratitis in Mice.CXCL9 and CXCL10 expression are critical for control of genital herpes simplex virus type 2 infection through mobilization of HSV-specific CTL and NK cells to the nervous systemGlutamine and leucine provide enhanced protective immunity against mucosal infection with herpes simplex virus type 1.Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis.Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.OT-1 mice display minimal upper genital tract pathology following primary intravaginal Chlamydia muridarum infection.Effector CD4+ T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cordsChemokines and Chemokine Receptors Critical to Host Resistance following Genital Herpes Simplex Virus Type 2 (HSV-2) InfectionDendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virusFas-mediated apoptotic signaling in the mouse brain following reovirus infectionRegulatory T cells are essential to promote proper CD4 T-cell priming upon mucosal infection.Cross-regulation between herpesviruses and the TNF superfamily membersCXCR3 deficiency increases susceptibility to genital herpes simplex virus type 2 infection: Uncoupling of CD8+ T-cell effector function but not migration.CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.Laryngopharyngeal reflux and herpes simplex virus type 2 are possible risk factors for adult-onset recurrent respiratory papillomatosis (prospective case-control study).Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral ReseFas/FasL and perforin-granzyme pathways mediated T cell cytotoxic responses in infectious bursal disease virus infected chickens.Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation.
P2860
Q26741484-840655EF-5BC1-46B6-8495-A446337B0273Q27324479-7F68BD0E-8B77-4C31-93B4-E989AC03EC10Q27490311-70AA4096-059A-433B-ADE6-3A9A311E30D0Q28730610-6B3B1031-5401-45A2-BCA9-9B1A86CA856AQ30496837-70EE61E8-35C8-4430-B1BD-4EB8F56C2579Q33625030-DC42824F-CFAE-4349-8B68-65E3EC50FC72Q34105712-017EABAB-A804-4A59-81E2-ACD6C6FF7120Q34376166-82794797-846E-4CD0-A34C-7AAF61933298Q34529742-5049D8C3-B0FF-4891-BD39-F5EC377A6BFBQ34781786-CCCA9667-D5A6-416E-A342-DCF3228830BFQ34850941-BF5EF60F-1A46-4076-8E52-9351480A0E9AQ35006398-36B4D702-0A59-49B6-8607-E6CAC06E8DFDQ35260078-D880F42A-580F-4E9A-BC30-0CD1D5CCFC3BQ35634352-87B7F421-54E9-42CF-B543-0C5706913504Q35658941-59FBCDDA-C179-4C6C-906E-D64A7815C753Q35692343-961EC4EC-1B3D-462F-B071-BB4AB54BE0FCQ35803679-6114C577-BBD6-4062-965B-4D567336ABD2Q36023204-3D4BAF86-2998-427E-849A-7E9215A863C7Q36124928-2E304631-16B1-4FA8-82D5-636FD09A5CD7Q36173155-93E2D7F5-B771-45C6-B403-462E2551BDBBQ36343355-F0C14112-D0A6-4935-A9C8-6454A34CCD82Q36431020-7C64B988-44F8-4B79-947B-BD0696B608F4Q36488868-EBAEA518-D6EB-403B-8E73-BD01C989ED65Q36740192-6A4289CD-FB75-42E7-8361-09BB27FFF7A2Q36759693-9A221BC8-8262-46D1-9110-64E9A6DC4648Q36810733-C4A15E02-8E6E-4B0C-89FB-16D8AE558F20Q36898906-4176FB05-256F-4651-AF84-6B275F8FA8CAQ36981179-8AF1892D-F858-4E99-A531-1F7EE438253EQ37019625-338A27AB-DC81-49E9-BAF8-8DE6DA02C2BEQ37204618-FABDA257-B648-47C5-8F86-1035BEB5B829Q37280197-6D53C8A6-556F-4EF3-B0A0-6FDB601C9D85Q37307520-8CFB2D50-3C07-422D-B479-A57652A0A4AEQ37333899-5DF2DE8F-2BDD-4100-9869-3AB7547AA405Q37679220-FE8121DC-08D5-4D79-B198-C25BB99152C5Q37727208-09C14D31-0422-47A2-BA8B-38C211FFF6F0Q37835427-A975E86D-AA4F-42BE-A740-151ECB518DE8Q37963480-16B8E7E7-A2D6-4597-8DE8-FF334C2598BBQ38947443-50A33555-DCFE-4A63-B37C-C4181A385E78Q42084275-CC4AD08D-C745-4AA8-900B-F34965A38DB6Q42241622-CC7EF1FF-A6F2-45D9-8A2D-F12E118DAAE7
P2860
Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@ast
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@en
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@nl
type
label
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@ast
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@en
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@nl
prefLabel
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@ast
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@en
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@nl
P2093
P2860
P1433
P1476
Clearance of herpes simplex vi ...... -mediated cytolytic mechanisms
@en
P2093
Chin-Fun Chu
Claudia Chalk
Jane E Strasser
Melanie E Dobbs
P2860
P304
14546-14554
P356
10.1128/JVI.79.23.14546-14554.2005
P407
P577
2005-12-01T00:00:00Z